Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vericel Corporation
AR-15512 missed the primary endpoints in a Phase IIb dry eye disease study that could have served as a pivotal trial, but Aerie’s drug hit enough signs and symptoms of the disease to justify a Phase III.
Phase III sub-analyses presented at ESMO show the drug providing a survival benefit in a complex subpopulation, as well as improvements to quality of life.
Moderna is hot on the heels of Pfizer with booster data for its COVID-19 vaccine, and could benefit from its rival being first to face potential skepticism from the US FDA over booster data for its vaccine.
Two companies are set to learn whether the European Medicines Agency will agree that their planned EU marketing applications merit an accelerated assessment.
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Aastrom Biosciences, Inc.
- Genzyme Biosurgery